Apparent absolute oral bioavailability in excess of 100% for a vitronectin receptor antagonist (SB-265123) in rat. I. Investigation of potential experimental and mechanistic explanations

Reference

• BASIT, A. W., NL \\ TON, J. M., SHORT, M. D., WADDINGTON, W. A., ELL, P. J. and LACEY, L. F., 2001, The effect of polyethylene glycol 400 on gastrointestinal transit: implications for the formulation of poorly-water soluble drugs. Pharmaceutical Research, 18, 1146–1150.
   Google Scholar
• BERGLUND, F., ENGBERG, A., PERSSON, E. and ULFENDAHL, H., 1969, Renal clearances of labelled inulin (inulin-carboxyl-14C, inulin-methoxy-3H) and a polyethylene glycol (PEG 1000) in the rat. Acta Physiologica Scandinavica, 76, 458–462.
   PubMedGoogle Scholar
• BIALER, M., Wu, W. H., LOOK, Z. M., SILBER, B. M. and YACOBI, A., 1987, Pharmacokinetics of cefixime after oral and intravenous doses in dogs: bioavailability assessment for a drug showing nonlinear serum protein binding. Research Communications in Chemical Pathology and Pharmacology, 56, 21–32.
   Google Scholar
• CURRY, S. H., LORENZ, A., CHU, P.-I., LIMACHER, M. and STACPOOLE, P. W., 1991, Disposition and pharmacodynamics of dichloroacetate (DCA) and oxalate following oral DCA doses. Biopharmaceutics and Drug Disposition, 12, 375–390.
   Google Scholar
• DARBAR, D., DELL'ORTO, S., WILKINSON, G. R. and RODEN, D. M., 1996, Loss of quinidine gluconate injection in a polyvinyl chloride infusion system. American Journal of Health-System Pharmacy, 53, 655–658.
   Google Scholar
• GIBALDI, M. and PERRIER, D., 1982, Pharmacokinetics (New York: Marcel Dekker).
   Google Scholar
• HUGGER, E. D., AUDUS, K. L. and BORCHARDT, R. T., 2002, Effects of poly(ethylene glycol) on efflux transporter activity in Caco-2 cell monolayers. Journal of Pharmaceutical Sciences, 91, 1980–1990.
   Google Scholar
• INSTITUTE OF LABORATORY ANIMAL RESOURCES, 1996, Guide to the Care and Use of Laboratory Animals (Washington: National Academy Press).
   Google Scholar
• JANSSEN, F. W., KIRKMAN, S. K., FENSELAU, C., STOGNIEW, M., HOFMANN, B. R., YOUNG, E. M. and RUELIUS, H. W., 1982, Metabolic formation of N- and 0-glucuronides of 3-(p-chlorophenyl)thiazolo [3,2-a]benzimidazole-2-acetic acid. Rearrangement of the 1-0-acyl glucuronide. Drug Metabolism and Disposition, 10, 599–604.
   PubMed Web of Science ®Google Scholar
• LI, J., DOBSON, G. L., MARIETTA, M. P., RHODES, G. R. and HIDALGO, I. J., 1997, In vivo determination of drug kinetic linearity and individual organ elimination by the accelerated infusion technique. Journal of Pharmacological and Toxicological Methods, 37, 47–53.
   PubMed Web of Science ®Google Scholar
• LUDDEN, T. M., 1991, Nonlinear pharmacokinetics: clinical implications. Clinical Pharmacokinetics, 20, 429–446.
   PubMed Web of Science ®Google Scholar
• MILLER, W. H., BONDINELL, W. E., COUSINS, R. D., ERHARD, K. F., JAKAs, D. R., KEENAN, R. M., Ku, T. W., NEWLANDER, K. A., Ross, S. T., HALTIWANGER, R. C., BRADBEER, J., DRAKE, F. H., GOWEN, M., HOFFMAN, S. J., HWANG, S.-M., JAMES, I. E., LARK, M. W., LECHOWSKA, B., RIEMAN, D. J., STROUP, G. B., VASKO-MOSER, J. A., ZEMBRYKI, D. L., AZZARANO, L. M., ADAMS, P. C., SALYERS, K. L., SMITH, B. R., WARD, K. W., JOHANSON, K. 0. and HUFFMAN, W. F., 1999, Orally bioavailable nonpeptide vitronectin receptor antagonists with efficacy in an osteoporosis model. Bioorganic and Medicinal Chemistry Letters, 9, 1807–1812.
   Google Scholar
• MILLER, W. H., KEENAN, R. M., WILLETTE, R. N. and LARK, M. W., 2000, Identification and in vivo efficacy of small-molecule antagonists of integrin 007133 (the vitronectin receptor). Drug Discovery Today, 5, 397–408.
   PubMed Web of Science ®Google Scholar
• SCHMIDT, L. E. and DALHOFF, K., 2002, Food-drug interactions. Drugs, 62, 1481–1502.
   PubMed Web of Science ®Google Scholar
• THRON, C. D., 1974, Linearity and superposition in pharmacokinetics. Pharmacological Reviews, 26, 3–31.
   PubMedGoogle Scholar
• TOZER, T. N., TANG-LIU, D. D.-S. and RIEGELMAN, S., 1981, Linear vs. nonlinear kinetics. In D. D. Breimer and P. Speiser (eds), Topics in Pharmaceutical Sciences (New York: Elsevier), pp. 3–17.
   Google Scholar
• UPTON, R. A. and WILLIAMS, R. L., 1986, The impact of neglecting nonlinear plasma-protein binding on disopyramide bioavailability studies. Journal of Pharmacokinetics and Biopharma-ceutics, 14, 365–379.
   Google Scholar
• VAN BREEMAN, R. B. and FENSELAU, C. C., 1986, Reaction of 1-0-acyl glucuronides with 4-(p-nitrobenzyl) pyridine. Drug Metabolism and Disposition, 14, 197–201.
   Google Scholar
• WARD, K. W., AZZARANO, L. M., BONDINELL, W. E., COUSINS, R. D., HUFFMAN, W. F., JAKAS, D. R., KEENAN, R. M., Ku, T. W., LUNDBERG, D., MILLER, W. H., MUMAW, J. A., NEWLANDER, K. A., PIRHALLA, J. L., ROETHKE, T. R., SALYERS, K. L., SOUDER, P. R., STELMAN, G. J. and SMITH, B. R., 1999a, Preclinical pharmacokinetics and interspecies scaling of a novel vitronectin receptor antagonist. Drug Metabolism and Disposition, 27, 1232–1241.
   PubMed Web of Science ®Google Scholar
• WARD, K. W., GRIFFITHS, R., LEVY, M. A. and SMITH, B. R., 2000, Evaluation of the utility of accelerated infusions for the determination of pharmacokinetic linearity. Journal of Pharmacology and Experimental Therapeutics, 293, 468–479.
   PubMedGoogle Scholar
• WARD, K. W., HARDY, L. B., KEHLER, J. R., AZZARANO, L. M. and SMITH, B. R., 2004, Apparent absolute oral bioavailability in excess of 100% for a vitronectin receptor antagonist (SB-265123) in rat. II. Studies implicating transporter-mediated intestinal secretion. Xenobiotica, 34, 367–377.
   PubMed Web of Science ®Google Scholar
• WARD, K. W., PROKSCH, J. W., AZZARANO, L. M., SALYERS, K. L., MCSURDY-FREED, J. E., MOLNAR, T. M., LEVY, M. A. and SMITH, B. R., 2001b, SB-239063, a potent and selective inhibitor of p38 MAP kinase: Preclinical pharmacokinetics and species-specific reversible isomerization. Pharmaceutical Research, 18, 1336–1344.
   Google Scholar
• WARD, K. W., PROKSCH, J. W., LEVY, M. A. and SMITH, B. R., 2001a, Development of an in vivo preclinical screen model to estimate absorption and bioavailability of xenobiotics. Drug Metabolism and Disposition, 29, 82–88.
   PubMed Web of Science ®Google Scholar
• WARD, K. W., SALTERS, K. L., AZZARANO, L. M., LUNDBERG, D., PIRHALLA, J. L., MILLER, W. H., ROETHKE, T. J., STELMAN, G. J. and SMITH, B. R., 1999b, Preclinical pharmacokinetics and interspecies scaling of a novel vitronectin receptor antagonist. Toxicological Sciences, 48, 207.
   Google Scholar
• YAMAOKA, T., TABATA, Y. and IKADA, Y., 1994, Distribution and tissue update of poly(ethylene glycol) with different molecular weights after intravenous administration to mice. Journal of Pharmaceutical Sciences, 83, 601–606.
   PubMed Web of Science ®Google Scholar